1887

Abstract

The pneumococcal surface protein PspA, a cell-wall-associated surface protein, is a promising component for pneumococcal vaccines. In this study, the distribution of the PspA family was determined in a panel of invasive and clinically important pneumococcal isolates from adults over 50 years of age, collected between 1995 and 2002. One thousand eight hundred and forty-seven recent isolates from invasive pneumococcal disease were obtained from seven Western countries, together with clinical data. An ELISA-based serological method was standardized in order to determine the PspA family and clade distribution. Molecular tests were used when isolates were non-typable by ELISA (PspA family typing by PCR). Only 42 (2·3 %) isolates were non-typable by ELISA and PspA family typing by PCR was performed. Finally, 3 isolates were considered as non-pneumococcal and 1844 were classified as follows: 749 (40·6 %) were PspA family 1, 1078 (58·5 %) were PspA family 2, 13 (0·7 %) were PspA family 1 and 2 and 4 (0·2 %) remained non-typable. The cross-reactivity of antibodies to PspAs of different clades was confirmed. In conclusion, inclusion of PspA family 1 and family 2 in future pneumococcal vaccines would ensure broad coverage of pneumococcal strains infecting people over 50 years of age.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46268-0
2006-02-01
2019-10-14
Loading full text...

Full text loading...

/deliver/fulltext/jmm/55/2/215.html?itemId=/content/journal/jmm/10.1099/jmm.0.46268-0&mimeType=html&fmt=ahah

References

  1. Baril, L., Briles, D. E., Crozier, P., King, J., Punar, M., Hollingshead, S. K. & McCormick, J. B. ( 2004; ). Characterization of antibodies to PspA and PsaA in adults over 50 years of age with invasive pneumococcal disease. Vaccine 23, 789–793.[CrossRef]
    [Google Scholar]
  2. Beall, B., Gherardi, G., Facklam, R. R. & Hollingshead, S. K. ( 2000; ). Pneumococcal pspA sequence types of prevalent multiresistant pneumococcal strains in the United States and of internationally disseminated clones. J Clin Microbiol 38, 3663–3669.
    [Google Scholar]
  3. Bogaert, D., Hermans, P. W., Adrian, P. V., Rumke, H. C. & de Groot, R. ( 2004; ). Pneumococcal vaccines: an update on current strategies. Vaccine 22, 2209–2220.[CrossRef]
    [Google Scholar]
  4. Brandileone, M. C., Andrade, A. L., Teles, E. M., Zanella, R. C., Yara, T. I., Di Fabio, J. L. & Hollingshead, S. K. ( 2004; ). Typing of pneumococcal surface protein A (PspA) in Streptococcus pneumoniae isolated during epidemiological surveillance in Brazil: towards novel pneumococcal protein vaccines. Vaccine 22, 3890–3896.[CrossRef]
    [Google Scholar]
  5. Briles, D. E., Hollingshead, S. K., King, J., Swift, A., Braun, P. A., Park, M. K., Ferguson, L. M., Nahm, M. H. & Nabors, G. S. ( 2000a; ). Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 182, 1694–1701.[CrossRef]
    [Google Scholar]
  6. Briles, D. E., Ades, E., Paton, J. C., Sampson, J. S., Carlone, G. M., Huebner, R. C., Virolainen, A., Swiatlo, E. & Hollingshead, S. K. ( 2000b; ). Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 68, 769–800.
    [Google Scholar]
  7. Brueggemann, A. B., Griffiths, D. T., Meats, E., Peto, T., Crook, D. W. & Spratt, B. G. ( 2003; ). Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 187, 1424–1432.[CrossRef]
    [Google Scholar]
  8. Eskola, J. ( 2000; ). Immunogenicity of pneumococcal conjugate vaccines. Pediatr Infect Dis J 19, 388–393.[CrossRef]
    [Google Scholar]
  9. Gor, D. O., Ding, X., Briles, D. E., Jacobs, M. R. & Greenspan, N. S. ( 2005; ). Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae. Infect Immun 73, 1304–1312.[CrossRef]
    [Google Scholar]
  10. Hollingshead, S. K., Becker, R. & Briles, D. E. ( 2000; ). Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 68, 5889–5900.[CrossRef]
    [Google Scholar]
  11. Jackson, L. A., Neuzil, K. M., Yu, O. & 7 other authors, for the Vaccine Safety Datalink ( 2003; ). Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 348, 1747–1755.[CrossRef]
    [Google Scholar]
  12. McCool, T. L., Cate, T. R., Moy, G. & Weiser, J. N. ( 2002; ). The immune response to pneumococcal proteins during experimental human carriage. J Exp Med 195, 359–365.[CrossRef]
    [Google Scholar]
  13. Mollerach, M., Regueira, M., Bonofiglio, L., Callejo, R., Pace, J., Di Fabio, J. L., Hollingshead, S., Briles, D. & the Streptococcus pneumoniae Working Group ( 2004; ). Invasive Streptococcus pneumoniae isolates from Argentinian children: serotypes, families of pneumococcal surface protein A (PspA) and genetic diversity. Epidemiol Infect 132, 177–184.[CrossRef]
    [Google Scholar]
  14. Nabors, G. S., Braun, P. A., Herrmann, D. J. & 8 other authors ( 2000; ). Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 18, 1743–1754.[CrossRef]
    [Google Scholar]
  15. Ogunniyi, A. D., Folland, R. L., Briles, D. E., Hollingshead, S. K. & Paton, J. C. ( 2000; ). Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun 68, 3028–3033.[CrossRef]
    [Google Scholar]
  16. Ren, B., Szalai, A. J., Thomas, O., Hollingshead, S. K. & Briles, D. E. ( 2003; ). Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect Immun 71, 75–85.[CrossRef]
    [Google Scholar]
  17. Ren, B., Szalai, A. J., Hollingshead, S. K. & Briles, D. E. ( 2004; ). Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun 72, 114–122.[CrossRef]
    [Google Scholar]
  18. Roche, H., Ren, B., McDaniel, L. S., Hakansson, A. & Briles, D. E. ( 2003; ). Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae. Infect Immun 71, 4498–4505.[CrossRef]
    [Google Scholar]
  19. Shaper, M., Hollingshead, S. K., Benjamin, W. H., Jr & Briles, D. E. ( 2004; ). PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin. Infect Immun 72, 5031–5040.[CrossRef]
    [Google Scholar]
  20. Swiatlo, E., Brooks-Walter, A., Briles, D. E. & McDaniel, L. S. ( 1997; ). Oligonucleotides identify conserved and variable regions of pspA and pspA-like sequences of Streptococcus pneumoniae. Gene 188, 279–284.[CrossRef]
    [Google Scholar]
  21. Vela Coral, M. C., Fonseca, N., Castaneda, E., Di Fabio, J. L., Hollingshead, S. K. & Briles, D. E. ( 2001; ). Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from Colombian children. Emerg Infect Dis 7, 832–836.[CrossRef]
    [Google Scholar]
  22. Whitney, C. G., Farley, M. M., Hadler, J. & 10 other authors, for the Active Bacterial Core Surveillance of the Emerging Infections Program Network ( 2003; ). Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348, 1737–1746.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.46268-0
Loading
/content/journal/jmm/10.1099/jmm.0.46268-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error